Please login to the form below

Not currently logged in
Email:
Password:

obesity

This page shows the latest obesity news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s semaglutide obesity trial hits the mark

Novo Nordisk’s semaglutide obesity trial hits the mark

Novo Nordisk’ s semaglutide obesity trial hits the mark. The injection helped adults lose up to 13.8% of their body weight in a year. ... Novo has made no secret of its ambition in obesity and the potential of semaglutide to transform the largely

Latest news

More from news
Approximately 40 fully matching, plus 329 partially matching documents found.

Latest Intelligence

  • Reading human behaviour to create a medical future Reading human behaviour to create a medical future

    improve. “Now, we are now at a stage where the biggest causes of morbidity and mortality are diabetes, obesity, CVD and hypertension and autoimmune conditions which require significant self-management, so

  • If a nudge doesn’t last forever, how do we ensure sustained behaviour change? If a nudge doesn’t last forever, how do we ensure sustained behaviour change?

    They have also. shown short-term effects in. reducing obesity, increasing hand-washing in hospitals and changing risky sexual behaviour in teenagers. ... Nudges aimed at reducing obesity through paying incentives to lose weight are very effective in the

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    With NASH appearing to be a long-term consequence of obesity it is perhaps not surprising to see that deals in this area have stolen the headlines, with candidates becoming the ... US due to the rise in obesity and it impacts 3-5% of the US population

  • A healthy challenge A healthy challenge

    Whether these challenges take the form of antibiotic resistance or obesity, I believe they need to be tackled in a holistic manner.”.

  • Harnessing commercial innovation Harnessing commercial innovation

    But a more recent entry into obesity, plus its interests in haemophilia and growth hormone disorders, provide important additions to its portfolio.

More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest appointments

  • Novo Nordisk appoints new senior principal clinical scientist Novo Nordisk appoints new senior principal clinical scientist

    Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.

  • MedImmune appoints Dr Christopher Rhodes MedImmune appoints Dr Christopher Rhodes

    In that position he led a large team of researchers focused on molecular mechanisms that control key functions in the pathogenesis of diabetes and obesity.

  • Anthony Zook resigns as Vivus CEO Anthony Zook resigns as Vivus CEO

    shareholders became unhappy with the way Vivus handled the launch of its obesity drug Qsymia (phentermine/ topiramat). ... This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia

  • Roche’s Torsten Hoffmann to join Zealand Pharma Roche’s Torsten Hoffmann to join Zealand Pharma

    In his new role at Zealand, Dr Hoffmann joins a more compact company focused on the discovery of drugs in cardio-metabolic diseases, diabetes and obesity.

  • Burson-Marsteller hires senior DH press officer Burson-Marsteller hires senior DH press officer

    In her previous role, Moore worked with both public health ministers and the chief medical officer, developing proactive and reactive communications strategies for issues including immunisation, genetics, obesity and alcohol.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Communicating the prevention message by Tam Fry

    At the  National Obesity Forum, we are constantly communicating in the media, offering solutions to prevent obesity in the future. ... charity. In 2005 he joined the Board of the National Obesity Forum and is now their spokesperson.

  • Is obesity the new smoking?

    He calls for a campaign to tackle obesity, or the alternative is a surge in killer diseases. ... He goes on to describes obesity as ‘ the new smoking’ – the biggest cause of cancer.

  • Commercial innovation in biotech organisations

    obesity. Image: Salma Jutt, Vice President of US Marketing and Head of Commercial Innovation.

  • ECHO Medical Communications

    ECHO Medical Communications. ECHO delivers dedicated medical communications specialising in the areas of endocrinology, cardiovascular disease, heart failure and obesity.

  • ECHO Medical Communications

    ECHO Medical Communications. ECHO delivers dedicated medical communications specialising in the areas of endocrinology, cardiovascular disease, heart failure and obesity.

More from PMHub
Approximately 4 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics